Last reviewed · How we verify
NCT06621134: AI chatbot
Comparing the Effectiveness of AI Chatbot with That of Telephone Hotline
trial testing AI Chatbot in Telephone Hotlines in 48 participants. Completed in 5 September 2024.
4 September 2024
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 3 September 2021 |
| Primary completion | 4 September 2024 |
| Estimated completion | 5 September 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- AI Chatbot
- Telephone hotline
Conditions studied
- Telephone Hotlines — all drugs for Telephone Hotlines →
- AI Chatbot — all drugs for AI Chatbot →
Sponsor
The University of Hong Kong
Who can join
Eligibility, any sex, with Telephone Hotlines or AI Chatbot. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COVID-19 pandemic has significantly impacted the wellbeing of people in Hong Kong, leading to social distancing policies and changes in healthcare service utilization. School closures and remote work have increased stress levels for parents and children. Vulnerable populations, such as low-income families and children with special needs, are at higher risk of maltreatment and mental health issues. Parental burnout has become a concern as parents juggle work, childcare, and education responsibilities. There is a need for research on the physical and mental health effects of COVID-19 on families and the potential role of AI in addressing these challenges. AI, particularly chatbots, can provide accessible healthcare information and support, aiding in early diagnosis and treatment. AI chatbots offer timely responses, accurate information, and continuous availability, making them valuable tools for remote health assistance. While AI chatbots are not without limitations, further research can help integrate them more effectively into healthcare services.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06621134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AI Chatbot
Trials testing the same drug.
- NCT07107152 — Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled · NA · completed
- NCT07300657 — Impact of an AI-Based Chatbot on Implant Patient Management: RCT · NA · completed
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06621134 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06621134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing